Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.79 |
| ▸ | KDR | P35968 | 8/20 | 0.79 |
| ▸ | RET | P07949 | 3/20 | 0.79 |
| ▸ | LCK | P06239 | 3/20 | 0.77 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.66 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.66 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
| ▸ | STK10 | O94804 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | JAK3 | P52333 | 1/20 | 0.65 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.65 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.65 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.65 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17836949 | 0.95 | EGFR (0.70) | EGFRKDRRETLCKAURKA | |
| SCHEMBL1257431 | 0.89 | EGFR (1.00) | EGFRKDRRETLCKMAPK14 | |
| SCHEMBL29515328 | 0.89 | EGFR (1.00) | EGFRKDRRETLCKMAPK14 | |
| Hydrochloric Acid SCHEMBL3533953 | 0.89 | AURKB (0.86) | EGFRKDRAURKAAURKBMAPK14 | |
| SCHEMBL6688859 | 0.89 | KDR (0.67) | EGFRKDRRETLCKAURKA | |
| SCHEMBL14964683 | 0.89 | EGFR (0.80) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL5239666 | 0.89 | KDR (0.80) | EGFRKDRRETLCKAURKA | |
| SCHEMBL3238919 | 0.88 | EGFR (0.70) | EGFRKDRRETLCKAURKA | |
| SCHEMBL4233633 | 0.88 | KDR (0.81) | EGFRKDRRETMAPK14EPHB2 | |
| Hydrochloric Acid SCHEMBL28325957 | 0.88 | AURKB (0.66) | EGFRKDRRETLCKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1680426-B1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1680426-A1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2004111055-A1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254205-A1 | Phenalene derivatives | LUK KIN-CHUN (US) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | EGFR 2929/4885KDR 2610/4885RET 1558/4885 |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR1I2, NR3C2 | EGFR 2407/4885KDR 2757/4885RET 1211/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | EGFR 2929/4885KDR 2610/4885RET 1558/4885 |
| US-20040254205-A1 | Phenalene derivatives | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 504/4885RET 10/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | EGFR 802/4885KDR 860/4885RET 665/4885 |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | NR1I3, NR3C2, NR1I2 | EGFR 2929/4885KDR 2610/4885RET 1558/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | EGFR 493/4885KDR 1628/4885RET 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.